PD-(L)1 Inhibitors Market to Remarkable Growth at a CAGR of 5% by 2034 in the 7MM| DelveInsight

In the increasingly crowded PD-(L)1 inhibitors market, KEYTRUDA maintains a dominant position, holding more than 50% market share in 2023 it is deeply entrenched with approval across 20 indications. Among the 10 approved drugs, early entrants OPDIVO and KEYTRUDA continue to command a…